ERBB2 and neoplasm: More recently, advancements in tumor-agnostic treatments came with the approval of trastuzumab deruxtecan-nxki (T-Dxd) by the FDA on 5 April 2024, for unresectable or metastatic HER2-positive solid tumors and reprotrectinib on 13 June 2024 for NTRK-fp solid tumors (Figure 2).